Mandate

Vinge has advised Titania Holding AB (publ) in connection with its listing on Nasdaq First North Growth Market

Vinge has advised Titania Holding AB (publ) (“Titania”) in connection with its listing on Nasdaq First North Growth Market. The prospectus was published on 29 November 2021 and the first day of trading was 10 December 2021.

The price in the offering was SEK 20 per class B share, corresponding to a market capitalization of all of Titania’s shares upon completion of the offering of approximately SEK 1.4 billion.

Titania is a fast-growing real estate company focusing on the Stockholm region. Its operations consist of project development, production and management. Titania participates throughout the entire value chain, from early stages of city and project development to land acquisitions, production and rental and eventually also long-term property management. Titania possesses expertise throughout all steps of the value chain and has capacity to carry out large projects within urban development, adding value in terms of increased social and financial sustainability.

Vinge’s team primarily consisted of David Andersson, Amanda Knutsson, Anna Grigorian and Anna Svensson (Capital Markets and Public M&A), Frida Ställborn (Real Estate), Kamyar Najmi and Benjamin Vafaeian (Banking and Finance).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025